182内分泌代謝疾患／糖尿病 SGLT2阻害薬文献 1） Zinman B, et al.：Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015；373：2117-2128 2） Anker SD, et al.：Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021；385：1451-1461 3） McGuire DK, et al.：Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol 2021；6：148-158 4） Bakris G, et al.：Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol 2020；15：1705-1714 5） Sako S, et al.：Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes. Diabetes 2023；72：1297-1306 6） Takeshita Y, et al.：Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. Diabetes Care 2022；45：2064-2075 7） American Diabetes Association. Standards of Care in Diabetes-2023. Diabetes Care 2023；46：S1-S91 8） The EMPA-KIDNEY Collaborative Group et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023；388：117-127 9） Yabe D, et al.：Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults （≥65 years） with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial （EMPA-ELDERLY）. Diabetes Obes Metab 2023；25：3538-354810） Yasuda M, et al.：Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report. J Diabetes Investig 2020；11：745-747後藤久典◎NASH合併2型糖尿病症例，夜間頻尿を有する症例に対する処方例処方例：トホグリフロジン（20 mg）1錠分1 朝食後◎慢性心不全，慢性腎臓病を有する2型糖尿病症例に対する処方例処方例：エンパグリフロジン（10 mg）1錠分1 朝食後My Best処方
元のページ ../index.html#9